Skip to main content

Table 5 Laboratory tests, treatment and prognosis of nineteen patients with anti-GABA-B receptor encephalitis

From: Clinical characteristics and prognostic analysis of anti-gamma-aminobutyric acid-B (GABA-B) receptor encephalitis in Northeast China

Case No.Anti-GABA-B receptor antibodiesOther antibodiesCSF routineTreatmentFollow-up period (months)OutcomesInitial mRS on admissionFollow-up mRS
SerumCSFSerumCSFWBC (× 106/L)Protein (g/L)ICULatency to immuno-therapy (days)ImmunotherapyAntiepileptic therapy
Favorable-prognosis group
 1++80.36+70MPLEV18Cured50
 2 (primary)++++180.57+30IVIGLEV    
 2 (recurrence)++180.747IVIG+MP17Improved41
 3++50.4330IVIG+MP2Improved51
 4++++++1030.5316MP27Improved21
 5++++420.39+18IVIGOXC20Cured50
 6++40.4415IVIG+MPVPA + LEV8Improved21
 7++190.3422IVIG5Cured20
 8++NMDAR+70.393Improved41
 9++80.3335MPCBZ3Improved51
 10++341.0917IVIG2Improved21
 11 (primary)+++200+29MPOXC    
 11 (recurrence)++60.24 LEV27Cured30
Poor-prognosis group
 12++Hu+430.39+15IVIGLEV9Death46
 13 (primary)+~+++~++CV2/CRMP5++CV2/CRMP5+++90.63+15IVIG+MPLEV    
 13 (recurrence)++CV2/CRMP5+CV2/CRMP5+90.63+8IVIG+MP13Death56
 14++++++Hu+Hu+960.37+27Death56
 15+++++70.37+12IVIG+MPOXC25Death56
 16++130.39+12Death56
 17++++210.49+13IVIG+MPLEV20Death56
 18++130.29+LEV3Death56
 19++310+5IVIG+MPOXC9Unchanged55
  1. CSF, cerebrospinal fluid; WBC, white blood cell; mRS, modified Rankin scale; NMDAR, anti-N-methyl-D-aspartate receptor antibody; Hu, anti-Hu antibody; CV2/CRMP5, anti-CV2/CRMP5 antibody; MP, methylprednisolone; IVIG, intravenous immunogloblin; LEV, levetiracetam; OXC, oxcarbazepine; VPA, valproic acid; CBZ, carbamazepine